drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An antibody–drug conjugate (T-DM1, ado-trastuzumab emtansine) that links the anti-HER2 monoclonal antibody trastuzumab to the maytansinoid microtubule inhibitor DM1 (emtansine). It binds HER2, is internalized, and releases DM1 to disrupt microtubules, causing cell-cycle arrest and apoptosis while also mediating ADCC via the trastuzumab component.
nci_thesaurus_concept_id
C82492
nci_thesaurus_preferred_term
Trastuzumab Emtansine
nci_thesaurus_definition
An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.
drug_mesh_term
Ado-Trastuzumab Emtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
An antibody–drug conjugate linking trastuzumab to the microtubule inhibitor DM1. Trastuzumab binds HER2 on tumor cells and is internalized; intracellular release of DM1 binds tubulin to disrupt microtubules, leading to cell‑cycle arrest and apoptosis. The antibody component also inhibits HER2 signaling and mediates antibody‑dependent cellular cytotoxicity (ADCC).
drug_name
Trastuzumab emtansine
nct_id_drug_ref
NCT05945927